Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding βA plaques in APP Tg2576 mice

Neuropathology and Applied Neurobiology

Volumn 30, Issue 5, 2004, Pages 491-502

  Puig, B ^a   Gomez Isla T ^b   Ribe E ^b   Cuadrado, M ^b   Torrejon Escribano, B ^c   Dalfo E ^a   Ferrer, Isidre ^a,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Unitat de Biologia de Bellvitge ^*  (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

A amyloid; APP; MAPK ERK; p38; SAPK JNK; tau; Tg2576

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN ANTIBODY; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LOCALIZATION; ENZYME SUBSTRATE; MOUSE; NEURITE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; SUPERNATANT; TRANSGENIC MOUSE; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN; ANIMALS; BLOTTING, WESTERN; BRAIN; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 9; NEURITES; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SENILE PLAQUES; TAU PROTEINS;

EID: 7044284920     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2004.00569.x     Document Type: Article

References (98)

1. Duyckaerts C, Dickson DW. Neuropathology of Alzheimer's disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Ed. D Dickson. Basel: ISN Neuropath Press, 2003; 47-68
2. Herreman A, Serneels L, Annaert W, Collen D, Schoonjans L, De Strooper B. Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol 2000; 2: 461-2
3. Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, Yankner BA. Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1. Nat Cell Biol 2000; 2: 463-5
4. Bertram L, Tanzi R. Genetics of Alzheimer's disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Ed. D Dickson. Basel: ISN Neuropath Press, 2003; 40-6
5. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR, Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 1992; 314: 315-21
6. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 1997; 409: 57-62
7. Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 1997; 78: 309-24
8. Goedert M, Spillantini MG, Davies SW. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 1998; 8: 619-32
9. Buée-Scherrer V, Goedert M. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett 2002; 515: 151-4
10. Xiao J, Perry G, Troncoso J, Monteiro MJ. Calcium-calmodulin-dependent kinase II is associated with paired helical filaments of Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55: 954-63
11. Pei JJ, Grundke-Iqbal I, Iqbal K, Bogdanovic N, Winblad B, Cowburn RF. Accumulation of cyclin-dependent kinase 5 (cdk-5) in neurons with early stages of Alzheimer's disease neuroflbrillary degeneration. Brain Res 1998; 29: 267-77
12. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. Distribution of glycogen synthase kinase 3 beta (GSK-3β) for Alzheimer disease neurofibrillary tangle. J Neuropathol Exp Neurol 1999; 58: 1010-119
13. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AL, Holbrook N, Siedlak SL, Harris PLR, Smith MA. Activation of extracellular receptor kinase (ERK) in Alzheimer's disease links oxidative stress to abnormal tau phosphorylation. Neuroreport 1999; 10: 2411-15
14. Knowles RB, Chin J, Ruff CT, Hyman BT. Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: implications for MAP kinase activation in Alzheimer's disease. J Neuropathol Exp Neurol 1999; 58: 1090-8
15. Schwab C, DeMaggio AJ, Ghoshal N, Binder LI, Kuret J, McGeer PL. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging 2000; 21: 503-10
16. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 880-8
17. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer's disease: the two hit hypothesis. Mech Ageing Dev 2001; 123: 39-46
18. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 2001; 60: 1190-7
19. Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 2001; 108: 1397-415
20. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, Cardozo A, Vinals F, Ribalta T. Phosphorylated MAP kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 2001; 11: 144-58
21. Pei JJ, Braak E, Braak H, Grundque-Iqbal K, Winblad W, Cowburn RF. Localization of active forms of c-Jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimer's Dis 2001; 3: 41-8
22. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease. Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2002; 104: 583-91
23. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 2001; 76: 435-41
24. Zhu X, Lee HG, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 2002; 11: 270-81
25. Zhu X, Rottkamp CA, Hartzier A, Sun Z, Takeda A, Boux H, Shimohama S, Perry G, Smith MA. Activation of MKK6. an upstream activator of p38, in Alzheimer's disease. J Neurochem 2001; 79: 311-18
26. Zhu X, Ogawa O, Wang Y, Perry G. Smith MA. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. J Neurochem 2003; 85: 87-93
27. Zhu X, Sun Z, Lee HG, Siedlak SL, Perry G. Smith MA. Distribution, levels, and activation of MEK1 in Alzheimer's disease. J Neurochem 2003; 86: 136-42
28. Busciglio J, Lorenzo A, Yeh J, Yankner BA. β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995; 14: 879-88
29. Ferreira A, Lu Q, Orecchio L, Kosik KS. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar Aβ. Mol Cell Neurosci 1997; 9: 220-34
30. Neve RL, Robakis NK. Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends Neurosci 1998; 21: 15-19
31. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopiau S, Johnson-Wood K, Khau K, Lee M, Lelbowitz P, Lleberburg I, Little S, Masliah E, McCoulogue L, Moutoya-Zavala M, Mucke L, Paganini L, Penimau E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wobziu B, Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 349: 704-6
32. Hsiao K, Chapman P, Nilsen S, Exkman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102
33. Borchelt DR, Ratovitsi T, van Lare J, Lee MK, Gozales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19: 939-45
34. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997; 94: 13287-92
35. Borchelt DR, Wong PC, Sisodia SS, Price DL. Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis. Brain Pathol 1998; 8: 735-57
36. Guenette SY, Tanzi RE. Progress toward valid transgenic mouse models for Alzheimer's disease. Neurobiol Aging 1999; 20: 201-11
37. van Leuven F. Single and multiple transgenic mice as models for Alzheimer's disease. Progr Neurobiol 2000; 61: 305-12
38. McGowan E, Pickord F, Dickson DW. Alzheimer animal models, models of Aβ deposition in transgenic mice. In Neurogeneration: The Molecular Pathology of Dementia and Movement Disorders. Ed. D Dickson. Basel: ISN Neuropath Press, 2003; 74-9
39. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997; 17: 7053-9
40. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related Aβ deposits and neuropil abnormalities. but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997; 56: 965-73
41. Holcomb L, Gordon MN, McGowan EYuX, Benkovic S, Janyzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenelin 1 transgenes. Nat Med 1998; 4: 97-100
42. Borchelt DR, Lee MK, Gozales V, Slunt HH, Ratovitsky T, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accumulation of proteolytic fragments of mutant presenilin 1 and accelerated amyloid deposition are co-regulated in transgenic mice. Neurobiol Aging 2002; 23; 171-7
43. Higgins LS, Holtzman DM, Rabin J, Mobley WC, Cordell B. Transgenic mouse brain histopathology resembles early Alzheimer's disease. Ann Neurol 1994; 35: 598-7
44. Masliah E, Sisk A, Mallory M, Games D. Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. J Neuropathol Exp Neurol 2001; 60: 357-68
45. Tomidokoro Y, Harigaya Y, Matsubara E, Ikeda M, Kawarabayashi T, Shirao T, Ishiguro K, Okamoto K, Younkin SG, Shoji M. Brain Aβ amyloidosis in APP (Sw) mice induces accumulation of presenilin-1 and. Tau J Pathol 2001; 194: 500-6
46. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-91
47. Otth C, Concha II, Arendt T, Stieler J, Schliebs R, González- Billault C, Maccioni RB. AβPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimer's Dis 2002; 4: 417-30
48. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998; 152: 871-7
49. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, Perry G. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998; 70: 2212-15
50. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 2002; 22: 3376-85
51. Ferrer I, Marti E, Tortosa A, Blasi J. Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission. J Neuropathol Exp Neurol 1998; 57: 218-25
52. Ferrer I, Blanco R, Carmona M. Differential expression of active, phosphorylation-dependent MAP kinases, MAPK/ERK. SAPK/JNK and p38. and specific transcription factor substrates following quinolinic acid excitotoxicity in the rat. Mol Brain Res 2001; 94: 48-58
53. Bugiani O, Gioccone G, Verga L, Pollo B, Guetti B, Frangione B, Tagliavini F. Alzheimer patients and Down patients: abnormal presynaptic terminals are related to cerebral pre-amyloid deposits. Neurosci Lett 1990; 119: 56-9
54. Lassmann H, Fisher P, Jellinger K. Synaptic pathology of Alzheimer's disease. Ann N Y Acad Sci 1993; 24: 59-64
55. Masliah E. Mechanisms of synaptic pathology in Alzheimer's disease. J Neural Transm 1998; 53: 147-58
56. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME. β-Amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001; 21: 7551-60
57. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. Biochem Biophys Acta 2000; 1502: 132-44
58. Nunomura A, Perry G, Aliv G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood C, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer's disease. J Neuropathol Exp Neurol 2001; 60: 759-67
59. Furuta A, Price DL, Pardo CA, Troncoso JC, Xu ZS, Taniguchi N, Martin LJ. Localization of Superoxide dismutase in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 1995; 146: 357-67
60. Smith MA, Richey PL, Kutty RK, Wiggert B, Perry G. Ultrastructural localization of heme oxygenase-1 to the neurofibrillary pathology of Alzheimer disease. Mol Chem Neuropathol 1995; 24: 227-30
61. De Leo ME, Borrello S, Passantino M, Palazzotti B, Mordente A, Daniele A, Filippini V, Galeotti T, Masullo C. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci Lett 1998; 250: 173-6
62. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 1997; 17: 5089-100
63. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J Neurochem 1997; 68: 255-64
64. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990; 250: 279-82
65. Forloni G, Chiesa R, Smiroldo S, Verga L, Salmona M, Tagliavini F, Angeretti N. Apoptosis mediated neurotoxicity induced by chronic application of β-amyloid fragment 25-35. Neuro Rep 1993; 4: 523-6
66. Watt JA, Pike CJ, Walencewicz-Wasserman AJ, Cotman CW. Ultrastructural analysis of β-amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res 1994; 661: 147-56
67. Forloni G. Neurotoxicity of β-amyloid and prion peptides. Curr Opin Neurol 1996; 9: 492-500
68. Estus S, Tucker HM, van Rooyen C, Wright S, Brigham EF, Wogulis M, Rydel RE. Aggregated amyloid-β protein induces cortical neuronal apoptosis and concomitant apoptotic pattern of gene induction. J Neurosci 1997; 17: 736-45
69. Cotman CW, Sue JH. Mechanisms of neuronal cell death in Alzheimer's disease. Brain Pathol 1996; 6: 493-506
70. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20: 154-9
71. Selznick LA, Holtman DM, Han BH, Gökden M, Srinavasan AN, Johnson EM, Roth KA. In situ immunodetection of neuronal caspase-3 activation in Alzheimer's disease. J Neuropathol Exp Neurol 1999; 58: 1020-6
72. Selkoe DJ. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol Clin 2000; 18: 903-22
73. Roth KA. Caspases, apoptosis, and Alzheimer's disease: causation, correlation and confusion. J Neuropathol Exp Neurol 2001; 60: 829-38
74. Reynolds CH, Nebreda AR, Gibb GM, Utton MA, Anderton BH. Reactivating kinase/p38 phosphorylates tau protein in vitro. J Neurochem 1997; 69: 191-8
75. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH. Stress-activated protein kinase/c-Jun N-terminal kinase phosphorylates tau protein. J Neurochem 1997; 68: 1736-44
76. Jenkins SM, Zinnerman M, Garner C, Johnson GV. Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J 2000; 345: 263-70
77. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and p38, and glycogen synthase kinase-3β. J Neurochem 2000; 74: 1587-95.
78. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 1999; 72: 2053-8
79. Song C, Perides G, Wang D, Liu YF. β-Amyloid peptide induces formation of actin stress fibers through p38 mitogen-activated protein kinase. J Neurochem 2002; 83: 828-36
80. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-31
81. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochem Biophys Acta 1997; 133: F85-104
82. Ham J, Eilers A, Whitfield J, Neame SJ, Shah B. c-Jun and the transcriptional control of neuronal apoptosis. Biochem Pharmacol 2000; 60: 1015-21
83. Mielke K, Herdegen T. JNK and p38 stress kinases: degenerative effectors of signal-transduction-cascades in the nervous system. Progr Neurobiol 2000; 61: 45-60
84. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000; 25: 257-60
85. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Dérijard B, Davis RJ. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996; 15: 2760-70
86. Raingeaud J, Gupta S, Rogers J, Dickens M, Han J, Uleviitch RJ, Davis RJ. Pro-inflammatory cytokines and environmental stress causes p38 MAP kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995; 270: 7420-6
87. Gupta S, Campbell D, Dérijard B, Davis RJ. Transcription factor ATF-2 regulation by the JNK signal transduction pathway. Science 1995; 267: 389-3
88. Herdegen T, Claret FX, Kallunki T, Martín-Villalba A, Winter C, Hunter T, Karin M. Lasting N-terminal phosphorylation of c-Jun and activation of JNK/SAPK kinases neuronal injury. J Neurosci 1998; 18: 5124-35
89. Ferrer I, Blanco R, Carmona M, Puig B, Dominguez I, Vinals F. Active, phosphorylation-dependent MAP kinases, MAPK/ERK, SAPK/JNK and p38, and specific transcription factor substrates are differentially expressed following systemic administration of kainic acid to the adult rat. Acta Neuropathol 2002; 103: 391-407
90. Daniels WM, Hendricks J, Salie R, Taljaard JJ. The role of the MAP-kinase superfamily in β-amyloid toxicity. Metab Brain Dis 2001; 16: 175-85
91. Jang JH, Surh YJ. β-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann N Y Acad Sci 2002; 973: 228-36
92. 2 and 4-hydroxynonenal mediate amyloid β-induced neuronal apoptosis by activating JNKs and p38 MAPKs. Exp Neurol 2003; 180: 144-55
93. Fogarty MP, Downer EJ, Campbell V. A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons. Biochem J 2003; 371: 789-98
94. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA. Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurocem 2001; 77: 157-64
95. Wei W, Norton DD, Wang X, Kusiak JW. Aβ 17-42 in Alzheimer's disease actives JNK and caspase-8 leading to neuronal apoptosis. Brain 2002; 125: 2036-43
96. Wei W, Wang X, Kusiak JW. Signaling events in amyloid β-peptide-induced neuronal death and insulin-like growth factor I protection. J Biol Chem 2002; 277: 17649-56
97. Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murphi S, Vaught JL, Scott RW. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activity, promotes survival and blocks multiple events associated with Aβ-induced cortical neuron apoptosis. J Neurochem 2001; 77: 849-63
98. Moechars D, Lorent K, van Leuven F. Premature death in transgenic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis. Neuroscience 1999; 91: 819-30